Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
6.96Last Year’s EPS
6.63Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive outlook driven by record 2025 revenue (>$3B), double-digit growth, strong Tyvaso performance (Q4 Tyvaso +12%, Tyvaso DPI +24%), near-term product filings and unblindings, and multiple transformative pipeline programs (Tresmi, super prostacyclin, IPF, transplant initiatives). Management acknowledged short-term variability in patient starts, distributor ordering seasonality, and emerging competition from Liquidia/Yutrepia. Key near-term catalysts are binary (trial unblindings and regulatory approvals), creating upside if positive but presenting execution risk if delayed or unsuccessful.Company Guidance
Record Annual Revenue and Growth
Full-year 2025 total revenue surpassed $3.0 billion for the first time in company history, representing 11% growth versus full-year 2024.
Fourth Quarter Revenue Increase
Q4 FY2025 total revenue was $790 million, a 7% increase year-over-year.
Tyvaso Strong Performance
Tyvaso generated $464 million in Q4 revenue, up 12% year-over-year, with Tyvaso DPI demonstrating robust 24% year-over-year growth.
Pipeline Milestones and Near-Term Unblindings
Upcoming unblindings: once-daily 'super prostacyclin' outcome study unblinding next week and the second pivotal Tyvaso IPF trial unblinding next month (TETON series). Management expects to file and commercially launch an IPF indication by no later than June 2027 if results confirm prior data.
Tresmi Soft Mist Inhaler (SMI) — Category Opportunity
Announced unsheathing of 'Tresmi', a proprietary treprostinil soft-mist inhaler claimed to reduce cough (the #1 dry-powder-related side effect) by up to ~90% in human studies to date; company intends to file for approval this year and commercially launch next year.
Transplantation and Regenerative Progress
Xeno program: 2 patients transplanted and doing well in FDA-approved trial; on track to enroll the 6-patient cohort by summer and pursue registration work in 2027 (commercial target ~2030). Miromatrix: completed first manufactured liver clinical trial enrollment and expects FDA guidance this year on regulatory path for liver and implanted kidney products.
Product and Clinical Data Enhancements
Commercial product improvements introduced (80-mcg cartridges and 96/112-mcg combination kits) to increase dosing flexibility and convenience; ARTISAN study preliminary data presented suggesting early high-dose treprostinil may reduce mean pulmonary arterial pressure and improve right ventricular function.
Reiterated Longer-Term Growth Target
Management reiterated a target to reach a $4.0 billion revenue run rate by the back half of 2027, stating this does not require the new product launches (which would be additive).
UTHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
UTHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $473.43 | $535.10 | +13.03% |
Oct 29, 2025 | $415.34 | $455.32 | +9.63% |
Jul 30, 2025 | $297.56 | $281.95 | -5.25% |
Apr 30, 2025 | $300.76 | $303.09 | +0.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does United Therapeutics (UTHR) report earnings?
United Therapeutics (UTHR) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is United Therapeutics (UTHR) earnings time?
United Therapeutics (UTHR) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is UTHR EPS forecast?
UTHR EPS forecast for the fiscal quarter 2026 (Q1) is 6.96.